Comparative Pharmacology
Head-to-head clinical analysis: DALFAMPRIDINE versus FIRDAPSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALFAMPRIDINE versus FIRDAPSE.
DALFAMPRIDINE vs FIRDAPSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium channel blocker that enhances neuronal transmission by prolonging repolarization and increasing neurotransmitter release in demyelinated neurons.
FIRDAPSE (amifampridine) is a potassium channel blocker that increases the release of acetylcholine from nerve terminals by prolonging the depolarization phase of the action potential, thereby enhancing neuromuscular transmission.
10 mg orally twice daily, 12 hours apart.
15 mg orally twice daily, with or without food.
None Documented
None Documented
5-6 hours in patients with normal renal function; prolonged to 15-20 hours in moderate renal impairment.
Clinical Note
moderateDalfampridine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Ticlopidine
"The metabolism of Ticlopidine can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Nicotine
"The metabolism of Nicotine can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Quinidine
Terminal elimination half-life is approximately 7-8 hours in adults with normal renal function; may be prolonged in renal impairment.
Renal excretion of unchanged drug (95%); fecal (<5%).
Primarily renal excretion as unchanged drug (~96%) with minor fecal elimination (~4%).
Category C
Category C
Potassium Channel Blocker
Potassium Channel Blocker
"The serum concentration of Quinidine can be increased when it is combined with Dalfampridine."